These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22610034)

  • 1. Design and synthesis of a novel class of CK2 inhibitors: application of copper- and gold-catalysed cascade reactions for fused nitrogen heterocycles.
    Suzuki Y; Oishi S; Takei Y; Yasue M; Misu R; Naoe S; Hou Z; Kure T; Nakanishi I; Ohno H; Hirasawa A; Tsujimoto G; Fujii N
    Org Biomol Chem; 2012 Jul; 10(25):4907-15. PubMed ID: 22610034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diversity-oriented synthesis of pyrazolo[4,3-b]indoles by gold-catalysed three-component annulation: application to the development of a new class of CK2 inhibitors.
    Hou Z; Oishi S; Suzuki Y; Kure T; Nakanishi I; Hirasawa A; Tsujimoto G; Ohno H; Fujii N
    Org Biomol Chem; 2013 May; 11(20):3288-96. PubMed ID: 23535832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2.
    Nie Z; Perretta C; Erickson P; Margosiak S; Almassy R; Lu J; Averill A; Yager KM; Chu S
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4191-5. PubMed ID: 17540560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
    Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
    Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
    Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
    Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid preparation of triazolyl substituted NH-heterocyclic kinase inhibitors via one-pot Sonogashira coupling-TMS-deprotection-CuAAC sequence.
    Merkul E; Klukas F; Dorsch D; Grädler U; Greiner HE; Müller TJ
    Org Biomol Chem; 2011 Jul; 9(14):5129-36. PubMed ID: 21625704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions.
    Akritopoulou-Zanze I; Wakefield BD; Gasiecki A; Kalvin D; Johnson EF; Kovar P; Djuric SW
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1480-3. PubMed ID: 21288717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2.
    Golub AG; Bdzhola VG; Briukhovetska NV; Balanda AO; Kukharenko OP; Kotey IM; Ostrynska OV; Yarmoluk SM
    Eur J Med Chem; 2011 Mar; 46(3):870-6. PubMed ID: 21276643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.
    Hundsdörfer C; Hemmerling HJ; Götz C; Totzke F; Bednarski P; Le Borgne M; Jose J
    Bioorg Med Chem; 2012 Apr; 20(7):2282-9. PubMed ID: 22377675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
    Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
    J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogs.
    Haddach M; Pierre F; Regan CF; Borsan C; Michaux J; Stefan E; Kerdoncuff P; Schwaebe MK; Chua PC; Siddiqui-Jain A; Macalino D; Drygin D; O'Brien SE; Rice WG; Ryckman DM
    Bioorg Med Chem Lett; 2012 Jan; 22(1):45-8. PubMed ID: 22169261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-substituted Indole-2 and 3-carboxamide derivatives as inhibitors of human protein kinase CK2: in vitro assay and molecular modelling study.
    Olgen S; Gratz A; Kurt ZK; Jose J
    Acta Chim Slov; 2013; 60(3):628-35. PubMed ID: 24169717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and structure-activity relationship of 2,6-disubstituted pyrazines, potent and selective inhibitors of protein kinase CK2.
    Fuchi N; Iura Y; Kaneko H; Nitta A; Suyama K; Ueda H; Yamaguchi S; Nishimura K; Fujii S; Sekiya Y; Yamada M; Takahashi T
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4358-61. PubMed ID: 22633690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
    Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
    Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: design of potent protein kinase CK2 inhibitors.
    Cozza G; Gianoncelli A; Bonvini P; Zorzi E; Pasquale R; Rosolen A; Pinna LA; Meggio F; Zagotto G; Moro S
    ChemMedChem; 2011 Dec; 6(12):2273-86. PubMed ID: 21972104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of protein kinase CK2 inhibitors using solvent dipole ordering virtual screening.
    Nakanishi I; Murata K; Nagata N; Kurono M; Kinoshita T; Yasue M; Miyazaki T; Takei Y; Nakamura S; Sakurai A; Iwamoto N; Nishiwaki K; Nakaniwa T; Sekiguchi Y; Hirasawa A; Tsujimoto G; Kitaura K
    Eur J Med Chem; 2015; 96():396-404. PubMed ID: 25912672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
    Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
    Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel indeno[1,2-b]indoloquinones as inhibitors of the human protein kinase CK2 with antiproliferative activity towards a broad panel of cancer cell lines.
    Hundsdörfer C; Hemmerling HJ; Hamberger J; Le Borgne M; Bednarski P; Götz C; Totzke F; Jose J
    Biochem Biophys Res Commun; 2012 Jul; 424(1):71-5. PubMed ID: 22728884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
    Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
    Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells.
    Pierre F; Regan CF; Chevrel MC; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Rice WG; Ryckman DM
    Bioorg Med Chem Lett; 2012 May; 22(9):3327-31. PubMed ID: 22460033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.